Mohamed Sheik Tharik Abdul Azeeze , Rajaguru Arivuselvam
{"title":"Immuno-informatics design of a multimeric epitope peptide-based vaccine against dengue virus serotype-2","authors":"Mohamed Sheik Tharik Abdul Azeeze , Rajaguru Arivuselvam","doi":"10.1016/j.vacune.2023.10.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Dengue viral infection affects approximately 130 countries worldwide. According to WHO reports, 40% of the global population lives in rural areas with a high risk of contracting dengue. Researchers have identified four distant strains of the dengue virus, and a single vaccine has not permanently controlled the emergence of all four distant strains. Therefore, a vaccine is required for each of the four strains to address the current situation.</p></div><div><h3>Objectives</h3><p>The objective of this study was to design a multi-epitope-based vaccine for the dengue virus-2 strain that elicits a robust immune response while being safe and non-allergenic.</p></div><div><h3>Results</h3><p><span>Firstly, we analyzed the envelope protein<span><span> for its physicochemical and antigenic properties. Next, we predicted MHC I, MHC II, and B-cell epitopes with high accuracy and evaluated their properties. Then, we constructed a vaccine using a suitable adjuvant and linkers, and predicted the secondary and tertiary structure of the vaccine, and the tertiary structure was validated. After conducting </span>molecular docking with toll-like receptors, we utilized the best-docked result for molecular stimulation. Finally, we analyzed the </span></span>immune stimulation against the vaccine, and the results showed positive immune responses from macrophages, DC cells, T-cells, and B-cells. Additionally, we found that the vaccine was excreted from the human body.</p></div><div><h3>Conclusions</h3><p>Our study demonstrates the potential of using immunoinformatic tools and immunological knowledge to design a multi-epitope-based vaccine for the dengue virus-2 strain. This approach could be applied to designing vaccines for other diseases, and further studies are required to validate its effectiveness in vivo<em>.</em></p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"24 4","pages":"Pages 380-393"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2445146023000687","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Dengue viral infection affects approximately 130 countries worldwide. According to WHO reports, 40% of the global population lives in rural areas with a high risk of contracting dengue. Researchers have identified four distant strains of the dengue virus, and a single vaccine has not permanently controlled the emergence of all four distant strains. Therefore, a vaccine is required for each of the four strains to address the current situation.
Objectives
The objective of this study was to design a multi-epitope-based vaccine for the dengue virus-2 strain that elicits a robust immune response while being safe and non-allergenic.
Results
Firstly, we analyzed the envelope protein for its physicochemical and antigenic properties. Next, we predicted MHC I, MHC II, and B-cell epitopes with high accuracy and evaluated their properties. Then, we constructed a vaccine using a suitable adjuvant and linkers, and predicted the secondary and tertiary structure of the vaccine, and the tertiary structure was validated. After conducting molecular docking with toll-like receptors, we utilized the best-docked result for molecular stimulation. Finally, we analyzed the immune stimulation against the vaccine, and the results showed positive immune responses from macrophages, DC cells, T-cells, and B-cells. Additionally, we found that the vaccine was excreted from the human body.
Conclusions
Our study demonstrates the potential of using immunoinformatic tools and immunological knowledge to design a multi-epitope-based vaccine for the dengue virus-2 strain. This approach could be applied to designing vaccines for other diseases, and further studies are required to validate its effectiveness in vivo.